BiotechTubeBiotechTube
Home/Pipeline/KRP-116 (Dexpanthenol/Fluocinonide)

KRP-116 (Dexpanthenol/Fluocinonide)

Atopic Dermatitis

Phase 3Active

Key Facts

Indication
Atopic Dermatitis
Phase
Phase 3
Status
Active
Company
KYORIN Pharmaceutical

About KYORIN Pharmaceutical

KYORIN Pharmaceutical is a mid-sized, revenue-generating Japanese pharmaceutical company with a diversified portfolio spanning prescription drugs, over-the-counter (OTC) products, and veterinary medicines. The company leverages its expertise in respiratory and urological diseases to maintain a stable revenue base from commercial products while investing in R&D for future growth. Its strategic focus includes lifecycle management of key brands and advancing its pipeline through internal research and selective partnerships.

View full company profile

Therapeutic Areas

RespiratoryUrologyOtolaryngologyGastroenterologyDermatology

Other Atopic Dermatitis Drugs

DrugCompanyPhase
LebrikizumabEli LillyPhase 3
DupixentSanofiCommercial
ASP2408Astellas PharmaPhase 2
KW-6356Kyowa KirinPhase 2
KHK4083Kyowa KirinPhase 2
Opzelura (ruxolitinib cream)Ono PharmaceuticalApproved
ONO-7913Ono PharmaceuticalPhase 2
KT-474Kymera TherapeuticsPhase 2
GRC 27864Glenmark PharmaceuticalsPhase 2
ARQ-234Arcutis BiotherapeuticsPreclinical/Phase 1
STAR-0310BioCryst PharmaceuticalsPhase 1
RezpegaldesleukinNektar TherapeuticsPhase 2b